WHITE PLAINS, NY, Apr 23, 2012 (MARKETWIRE via COMTEX) —
Orgenesis Inc.
/quotes/zigman/6473007 ORGS
-12.70%
(“Orgenesis” or the “Company”), a
development stage company with a novel therapeutic technology
dedicated to convert a patient’s own liver cells into functional
insulin-producing cells as a treatment for diabetes, is very pleased
to announce the appointment of Dr. G. Alexander Fleming, M.D. to the
Company’s Scientific Advisory Board.
Dr. Fleming is a board certified endocrinologist with medical and
research training at Emory, Vanderbilt, and National Institutes of
Health. He served as reviewer and supervisory medical officer for 12
years at the FDA and brings extensive clinical experience and
regulatory responsibility in the therapeutic area of diabetes and
other general metabolic, bone, and endocrine disorders, growth and
development, nutrition, lipid-lowering compounds, and reproductive
indications. He led reviews of landmark approvals including those of
the first statin, insulin analog, metformin, PPAR-agonist, and growth
hormone for non-GH deficiency indications. He was responsible for the
regulation of the earliest biotech products including human insulin
and growth hormone. Dr. Fleming helped to shape a number of FDA
policies and practices related to therapeutic review and regulatory
communication and represented FDA at the International Conference on
Harmonisation (ICH) and the World Health Organization, where he was
stationed in 1992-93.
He serves on numerous scientific advisory boards, expert committees,
and corporate boards. He has continued to promote dialogue and
creativity within the community of therapeutic developers. Dr.
Fleming has authored the book “Optimizing Development of Therapies
for Diabetes” and a wide variety of scientific and policy
publications. He has served as an invited editorialist to The New
England Journal of Medicine and as a commentator on National Public
Radio.
Company CEO Jacob BenArie commented, “As we continue to move towards
advanced stage trials of our technology, the need to ensure our
research is not only scientifically sound, but also compliant with
senior medical regulatory approval organizations is of paramount
importance. With the advice and guidance of Dr. Fleming we feel
certain that we can focus our efforts efficiently in order to
maximize our ability to achieve our stated goals as quickly as
possible.”
Dr. Fleming responded, “I am honored to support a program that not
only has major potential for helping patients but is driven by
fascinating, elegant science. I am focusing my passion and energy
around solutions to restore normal insulin secretion in people with
diabetes, which is the fundamental unmet clinical need stretching
across the entire spectrum of diabetes. I believe Orgenesis can
advance Sarah Ferber’s technology into a breakthrough treatment if
not cure of T1 diabetes.”
Orgenesis invites interested readers to visit our website at
www.orgenesis.com to find out more about the Company and its goal to
bring about the end of diabetes as we now know it.
Further details of the Company’s business, finances, appointments and
agreements can be found as part of the Company’s continuous public
disclosure as a reporting issuer under the Securities Exchange Act of
1934 filed with the Securities and Exchange Commission’s (“SEC”)
EDGAR database. For more information visit:
www.orgenesis.com .
About Orgenesis Inc.
/quotes/zigman/6473007 ORGS
-12.70%
Orgenesis is a development stage
company with a novel therapeutic technology that employs a molecular
and cellular approach directed at converting a patient’s own liver
cells into functional insulin producing cells, as a treatment for
diabetes. The Company believes that converting the diabetic patient’s
own tissue into insulin-producing cells overcomes the problem of
donor shortage and removes the risk of transplant rejection. If
successful, this could mean the end of diabetes as we now know it.
For more information visit:
www.orgenesis.com .
Notice Regarding Forward-Looking Statements
This news release
contains “forward-looking statements” which are not purely
historical. Such forward-looking statements include, among other
things, the expectations of management that our regeneration
technology can be developed as therapeutic treatment for diabetes. No
assurance can be given that any of the events anticipated by the
forward-looking statements will occur or, if they do occur, what
benefits the Company will obtain from them. Actual results could
differ from those projected in any forward-looking statements due to
numerous factors. Such factors include, among others, the inherent
uncertainties associated with new projects and development stage
companies .which include, without limitation, the potential failure
of development candidates to advance through preclinical studies or
demonstrate safety and efficacy in clinical testing and the ability
to pass clinical trials so as to move on to the next phase, our
ability to retain key employees and our ability to finance
development or satisfy the rigorous regulatory requirements for new
medical procedures. Competitors may develop better or cheaper
alternatives to our products. These forward-looking statements are
made as of the date of this news release, and we assume no obligation
to update the forward-looking statements, or to update the reasons
why actual results could differ from those projected in the
forward-looking statements. Investors should refer to the risk
factors disclosure outlined in our periodic reports filed from
time-to-time with the Securities and Exchange Commission.
On Behalf of the Board
Orgenesis Inc.
Vered Caplan, Chairperson
Contact:
Investor Relations
Crescendo Communications, LLC
Email: orgs@crescendo-ir.com
Tel: +1-877-560-9060
www.orgenesis.com
SOURCE: Orgenesis Inc.
mailto:orgs@crescendo-ir.com
http://www.orgenesis.com/
Copyright 2012 Marketwire, Inc., All rights reserved.
/quotes/zigman/6473007
Add to portfolio
ORGS
/quotes/zigman/6473007
Add to portfolio
ORGS
